Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Short Communication

Emergence of BA.4/BA.5 Omicron Sub-lineages and Increased SARSCoV- 2 Incidence in Senegal

Author(s): Moussa Moise Diagne*, Amadou Diallo, Safietou Sankhe, Ndeye Marieme Top, Mouhamed Kane, Maimouna Mbanne, Martin Faye, Mamadou Aliou Barry, Ndongo Dia, Amadou Alpha Sall, Cheikh Loucoubar and Ousmane Faye

Volume 3, Issue 6, 2022

Published on: 27 December, 2022

Article ID: e081222211778 Pages: 4

DOI: 10.2174/2666796704666221208122043

Price: $65

Abstract

Background: The Omicron variant B.1.1.529 has led to a new dynamic in the COVID-19 pandemic, with an increase in cases worldwide. Its rapid propagation favors the emergence of novel sublineages, including BA.4 and BA.5. The latter has shown increased transmissibility compared to other Omicron sub-lineages. In Senegal, the emergence of the Omicron variant in December 2021 characterized the triggering of a short and dense epidemiological wave that peaked at the end of February. This wave was followed by a period with a significant drop in the number of COVID-19 cases, but an upsurge in SARS-CoV-2 infection has been noted since mid-June.

Objective: The purpose of this brief report is to give an update regarding the genomic situation of SARSCoV- 2 in Dakar during this phase of recrudescence of cases.

Methods: We performed amplicon-based SARS-CoV-2 sequencing on nasopharyngeal swab samples from declared COVID-19 patients and outbound travelers that tested positive.

Results: Ongoing genomic surveillance activities showed that more than half of recent COVID-19 cases were due to the BA.4 and BA.5 sub-lineages that share two critical mutations associated with increased transmissibility and immune response escape. The circulation of recombinants between Omicron sublineages was also noted.

Conclusion: Despite the lack of proven severity of BA.4 and BA.5 sub-lineages, their increased transmissibility causes a rapid spread of the virus, hence a surge in the number of cases. This rapid spread constitutes a greater risk of exposure for vulnerable patients. To tackle this issue, any increase in the number of cases must be monitored to support public health stakeholders. Therefore, genomic surveillance is an ever-essential element in managing this pandemic.

Graphical Abstract

[1]
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265-9.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[2]
WHO. Coronavirus (COVID-19) Dashboard Available from: https://covid19.who.int (Accessed on: 29th July 2022).
[3]
World Health Organization Regional Office for the Eastern Mediterranean. Update on COVID-19 in the Eastern Mediterranean Region 2020. Available from: http://www.emro.who.int/media/news/update-on-covid-19-in-the-eastern- mediterranean-region.html (Accessed on: 29th July 2022).
[4]
Dia N, Lakh NA, Diagne MM, et al. COVID-19 outbreak, Senegal, 2020. Emerg Infect Dis 2020; 26(11): 2771-3.
[http://dx.doi.org/10.3201/eid2611.202615] [PMID: 33054907]
[5]
WHO Coronavirus (COVID-19) Dashboard Available from: https://covid19.who.int./region/afro/country/sn (Accessed on: 27th September 2022).
[6]
Tegally H, San JE, Cotten M, et al. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. Science 2022; 378(6615): eabq5358.
[http://dx.doi.org/10.1126/science.abq5358] [PMID: 36108049]
[7]
Coronavirus Pandemic (COVID-19)-the data.. Available from: http://ourworldindata.org/coronavirus-data?country=~SEN (Accessed on: 30 July 2022).
[8]
Press release from the institut pasteur in dakar on the omicron variant. 2021. Available from: https://www.pasteur.sn/en/news/actualite-covid/press-release-institut-pasteur-dakar-omicron-variant (Accessed on: 30 July 2022).
[9]
Diédhiou CK, Padane A, Gueye K, et al. Heterogeneity of the Omicron variant in Senegal. New Microbes New Infect 2022; 47: 100990.
[http://dx.doi.org/10.1016/j.nmni.2022.100990] [PMID: 35747620]
[10]
Kandeel M, Mohamed MEM, Abd El-Lateef HM, Venugopala KN, El-Beltagi HS. Omicron variant genome evolution and phylogenetics. J Med Virol 2022; 94(4): 1627-32.
[http://dx.doi.org/10.1002/jmv.27515] [PMID: 34888894]
[11]
Weng S, Shang J, Cheng Y, et al. Genetic differentiation and diversity of SARS-CoV-2 Omicron variant in its early outbreak. Biosafety and Health 2022; 4(3): 171-8.
[http://dx.doi.org/10.1016/j.bsheal.2022.04.004] [PMID: 35496653]
[12]
Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med 2022; 28(9): 1785-90.
[http://dx.doi.org/10.1038/s41591-022-01911-2] [PMID: 35760080]
[13]
CDC-COVID Data Tracker. Available from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions (Accessed on: 27 September 2022).
[14]
Barry MA, Arinal F, Talla C, et al. Performance of case definitions and clinical predictors for influenza surveillance among patients followed in a rural cohort in Senegal. BMC Infect Dis 2021; 21(1): 31.
[http://dx.doi.org/10.1186/s12879-020-05724-x] [PMID: 33413174]
[15]
O’Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol 2021; 7(2): veab064.
[http://dx.doi.org/10.1093/ve/veab064] [PMID: 34527285]
[16]
Talla C, Loucoubar C, Roka JL, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: A national population-based cross-sectional survey, between October and November 2020. IJID Regions 2022; 3: 117-25.
[http://dx.doi.org/10.1016/j.ijregi.2022.02.007] [PMID: 35720135]
[17]
Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022; 387(1): 86-8.
[http://dx.doi.org/10.1056/NEJMc2206576] [PMID: 35731894]
[18]
Ding K, Jiang W, Xiong C, Lei M. Turning point: A new global COVID‐19 wave or a signal of the beginning of the end of the global COVID‐19 pandemic? Immun Inflamm Dis 2022; 10(4): e606.
[http://dx.doi.org/10.1002/iid3.606] [PMID: 35349754]
[19]
Zhang Y, Zhang T, Fang Y, Liu J, Ye Q, Ding L. SARS-CoV-2 spike L452R mutation increases Omicron variant fusogenicity and infectivity as well as host glycolysis. Signal Transduct Target Ther 2022; 7(1): 76.
[http://dx.doi.org/10.1038/s41392-022-00941-z] [PMID: 35264568]
[20]
Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022; 608(7923): 603-8.
[http://dx.doi.org/10.1038/s41586-022-05053-w] [PMID: 35790190]
[21]
Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 2022; 185(14): 2422-2433.e13.
[http://dx.doi.org/10.1016/j.cell.2022.06.005]
[22]
Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022; 608(7923): 593-602.
[http://dx.doi.org/10.1038/s41586-022-04980-y] [PMID: 35714668]
[23]
Khan K, Karim F, Ganga Y, et al. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat Commun 2022; 13(1): 4686.
[http://dx.doi.org/10.1038/s41467-022-32396-9]
[24]
Abu-Raddad LJ, Chemaitelly H, Bertollini R. National study group for COVID-19 epidemiology. Severity of SARS-CoV-2 reinfections as compared with primary infections. N Engl J Med 2021; 385(26): 2487-9.
[http://dx.doi.org/10.1056/NEJMc2108120]
[25]
Abdelhamid HN, Badr G, Bertollini R. Nanobiotechnology as a platform for the diagnosis of COVID-19: A review. Nanotechnol Environ Eng 2021; 6(1): 19.
[http://dx.doi.org/10.1007/s41204-021-00109-0]
[26]
Rahman MM. Progress in electrochemical biosensing of SARS-CoV-2 virus for COVID-19 management. Chemosensors 2022; 10(7): 287.
[http://dx.doi.org/10.3390/chemosensors10070287]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy